logo

Nrx Pharmaceuticals, Inc. (NRXP)



Trade NRXP now with
  Date
  Headline
12/5/2022 6:48:05 AM NRx Pharma Names Carrie Carretta SVP Of Clinical Development And Medical Affairs
12/2/2022 6:48:56 AM NRx Receives Nasdaq Notice Of Listing Compliance
12/2/2022 6:47:00 AM NRx Receives Nasdaq Notice of Listing Compliance (Press Release)
11/14/2022 6:53:53 AM NRx Pharmaceuticals Q3 Net Loss/shr $0.14 Vs. Loss/shr $0.72 Last Year
11/14/2022 1:17:24 AM Relief Therapeutics And NRx Pharma Announce Execution Of Definitive Settlement Agreements
11/9/2022 6:51:22 AM NRx Pharma Says Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process
11/7/2022 6:48:40 AM NRx Pharma Closes $11 Mln Unsecured Debt Financing
8/15/2022 6:52:44 AM NRx Pharma Q2 Net Loss $7.0 Mln Vs Loss Of $0.1 Mln Last Year
7/13/2022 7:17:35 AM NRx Pharma Appoints Stephen Willard As CEO
7/1/2022 7:36:29 AM NRx : FDA Declines Emergency Use Authorization For ZYESAMI For Subgroup Of Patients With Critical COVID-19
6/10/2022 11:55:19 PM NRx Pharma Says FDA Denies Breakthrough Therapy Designation Request For ZYESAMI
6/7/2022 9:12:31 PM NRx Pharma Appoints Seth Van Voorhees As CFO And Treasurer Effective June 13
5/26/2022 12:07:45 AM NRx Pharmaceuticals Announces DSMB Update On NIH Study Of ZYESAMI In Critical COVID-19
5/16/2022 7:32:27 AM NRx Pharma Q1 Net Loss $13.4 Mln Or $0.21/shr Vs Loss Of $25.5 Mln, Or $0.71/shr Prior Year